Fiche publication
Date publication
juin 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha
Tous les auteurs :
Gaspar N, Rey A, Berard PM, Michon J, Gentet JC, Tabone MD, Roche H, Defachelles AS, Lejars O, Plouvier E, Schmitt C, Bui B, Boutard P, Taque S, Munzer M, Vannier JP, Plantaz D, Enz-Werle N, Oberlin O
Lien Pubmed
Résumé
AIM OF THE STUDY: To determine whether a risk factor adapted chemotherapy would improve the outcome of non-metastatic bone Ewing's sarcoma. METHODS: Standard risk tumours (SR, good histological response to chemotherapy or small unresected tumours) received the previous EW88 chemotherapy. Ifosfamide/etoposide (IE) were introduced after 3 courses of cyclophosphamide/doxorubicine when tumour regression was 100ml). High risk tumours (HR, histological poor response >30% residual cells or clinical poor response
Référence
Eur J Cancer. 2012 Jun;48(9):1376-85
